Several of these strategies have employed prostate-specific (like PSA) or tumor specific antigens for directing responses [125]; for sipuleucel-T, which is an autologous cellular immunotherapy using the antigen presenting cell precursors from the patient, the target molecule is prostate acid phosphatase (PAP), and in vitro activated cells are reinfused in the patient, which resulted in a significant improvement in overall survival in the phase 3 IMPACT clinical trial [126]. The gene discussed is ACP3; the disease is neoplasm.